In this pilot study, influenced by the past success of antibody-drug conjugates and tumor-targeted nanocarriers, fluorescently-labeled model micelles were modified with multiple anti-CD276 antibodies (CD276Ab), then tested for their efficiency in targeting tumor-derived cells (Figure 1). This evidence concerns the gene CD276 and neoplasm.